Alnylam Pharmaceuticals (ALNY) PT Raised to $119 at BMO Capital on Regeneron Deal
Tweet Send to a Friend
BMO Capital analyst Do Kim raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $119.00 (from $106.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
